Prescription drug coupons: Evolution and need for regulation in direct-to-consumer advertising

Mackey, Tim K.; Yagi, Nozomi; Liang, Bryan A.

doi:10.1016/j.sapharm.2013.08.002

Cited by 12 publications

(9 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Various criteria have been proposed for determining the “fair” price when new drugs are introduced in the market . These proposals include determining the marginal clinical benefit of new drugs (value‐based pricing) and incorporating criteria, such as the seriousness of the disease, the availability of other therapies to treat the disease, the cost to the patient if the medicine is not reimbursed, and the overall social value of that drug . The problem is that without having easily accessible data on cost and economic viability considerations, price‐setting approaches may lead to higher prices if drugs are clinically more effective and more expensive .…”

Section: Policies Designed To Reduce Branded Pharmaceutical Pricesmentioning

confidence: 99%

“…35,47,81 The problem is that without having easily accessible data on cost and economic viability considerations, price-setting approaches may lead to higher prices if drugs are clinically more effective and more expensive. 69 Once drugs are in the market, suggested strategies include increased price transparency 60,82 and price negotiations. 71,72 Developing Innovative Pricing Policies…”

Section: Decreasing Market Demandmentioning

confidence: 99%

See 1 more Smart Citation

Reducing Branded Prescription Drug Prices: A Review of Policy Options

et al. 2017

View full text Add to dashboard Cite

The high prices of specialty pharmaceuticals are causing some public programs to ration care and many private insurers, including Medicare drug plans, to place specialty drugs on high cost-sharing tiers. As a result, access to these drugs is often restricted, and only a small portion of the population with a disease may receive treatment. This concern has generated a wide range of proposed solutions. We conducted a literature review and identified 52 solutions in the peer-reviewed literature that we classified into five broad categories: revising the patent system, encouraging research to increase development of new drugs, altering pharmaceutical regulation, decreasing market demand, and developing innovative pricing strategies. We discuss the rationale for these five approaches and summarize the proposed solutions. We also discuss four empirical issues that are particularly important in any discussion of policy options.

show abstract

Section: Policies Designed To Reduce Branded Pharmaceutical Pricesmentioning

confidence: 99%

Section: Decreasing Market Demandmentioning

confidence: 99%

Reducing Branded Prescription Drug Prices: A Review of Policy Options

et al. 2017

View full text Add to dashboard Cite

show abstract

“…6,19 So far, eDTCA is not regulated well by the FDA, which released draft guidance on the use of "interactive promotional media" by industry only recently, in early 2014, and the draft is subject to further comments and finalization. 20,21 The nature of the Internet means that eDTCA has the ability to cross country borders and spread globally, despite its prohibition in almost all countries.…”

Section: Shining the Light On Physician-directed Promotion But Not Dmentioning

confidence: 99%

It's Time to Shine the Light on Direct-to-Consumer Advertising

Mackey

Liang

2015

The Annals of Family Medicine

View full text Add to dashboard Cite

Pharmaceutical marketing is undergoing a transition as the business, delivery, and consumption of health care have increasingly become part of a growing digital landscape. Changes in pharmaceutical promotion also coincide with federal "sunshine" regulations newly implemented under the Affordable Care Act that require disclosure of certain marketing and industry payments to physicians. Collectively, these trends could lead to fundamental shifts in physician-directed and direct-to-consumer advertising (DTCA) that have yet to be adequately identified or explored. In response, we advocate for greater DTCA transparency, especially in the emerging digital forms of DTCA, to complement forthcoming sunshine transparency data. This will allow more robust study and understanding of changes in overall pharmaceutical marketing trends and their impact on health care consumption and behavior. This can also lead to more targeted state and federal policy interventions leveraging existing federal transparency regulations to ensure appropriate marketing, sales, and consumption of pharmaceutical products. BACKGROUND Over the past few decades, US pharmaceutical marketing has evolved in new and unexpected ways, as the business of health care has become part of a growing "eHealth" landscape. Increasingly, patients and other consumers, clinicians, and the industry have started to embrace emerging forms of digital technology (eg, the "health Internet," mobile health applications, self-tracking devices, and social media) that can influence health care information sourcing, consumption, and delivery. As an indication of this shift to "all things digital," the Pew Research Internet Project reports that 72% of surveyed US adults looked for health information online within the past year, 69% track at least 1 health indicator such as weight, exercise, symptoms, blood pressure, or sleeping patterns (with 21% of respondents using a form of technology to do so), and 52% of smartphone users use their devices to search for medical/health information. 1With consumers increasingly using information technology to deal with health issues, and with pharmaceutical manufacturers using directto-consumer advertising (DTCA) on the Internet, in social media, and through mobile applications (collectively "eDTCA"), [3][4][5][6] traditionally dominant forms of pharmaceutical marketing, which include physician-directed promotion and advertising in traditional media (eg, television, radio, print, and outdoor advertisements) might also be changing. 8 This led to a proliferation of drug advertisements on TV and in print to which the vast majority of Americans were exposed, likely prompting patients to request a promoted drug from their physician. 9,10 After hitting a peak of $5.89 billion in 2006, DTCA began to decline, with spending estimated to be $4.37 billion in 2010. This decrease has largely been attributed to dwindling drug pipelines, blockbuster patent expirations, and the recent global economic slowdown, 11-13 although certain subcategories (eg, t...

show abstract

“…There are many histories of the practice of medicine in the United States and a few of the pharmaceutical industry [5][6][7][8][9] and of the history of patent law, but Gabriel has written a critical history of the interwoven nature of the three and the underlying influence of treating health care as a commodity.…”

Section: Drugs and Money In The Unitedmentioning

confidence: 99%

Medical monopoly: intellectual property rights and the origins of the modern pharmaceutical industry

2015

Choice Reviews Online

View full text Add to dashboard Cite

Prescription drug coupons: Evolution and need for regulation in direct-to-consumer advertising

Cited by 12 publications

References 19 publications

Reducing Branded Prescription Drug Prices: A Review of Policy Options

Reducing Branded Prescription Drug Prices: A Review of Policy Options

It's Time to Shine the Light on Direct-to-Consumer Advertising

Medical monopoly: intellectual property rights and the origins of the modern pharmaceutical industry

Contact Info

Product

Resources

About